📰 David Angulo News
David Angulo News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from David Angulo. Real-time updates on events, politics, business and more.
January 5, 2024
JERSEY CITY, N.J., Jan. 05, 2024 -- SCYNEXIS, Inc. , a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today...
January 5, 2024
JERSEY CITY, N.J., Jan. 05, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today
October 26, 2023
Vanesa Gastellu, 31, went to trial on a murder charge for the killing of 23-year-old Christina Garcia. A bystander discovered the victim's body on the morning of Aug. 5, 2020 near the 3100 block of Main Street.
October 26, 2023
Vanesa Gastellu, 31, pleaded guilty in the killing of 23-year-old Christina Garcia. Prosecutors allege the killing was a gang hit against the victim who was blamed for another person's death.
September 14, 2023
Vanesa Gastellu, 31, is accused of murder in death of Christina Garcia, 23, found in a Chua Vista field in August 2020
September 14, 2023
A woman executed her former friend in Chula Vista because she believed the victim had caused her boyfriend to be fatally shot by police, a prosecutor said Wednesday, while a defense attorney argued the victim was actually shot to death by gang members who set her client up to take the fall.
September 14, 2023
A woman executed her former friend in Chula Vista because she believed the victim had caused her boyfriend to be fatally shot by police, a prosecutor said...
September 13, 2023
The victim's body was discovered on the morning of Aug. 5, 2020 in a field near the 3100 block of Main Street.
August 15, 2023
SCYNEXIS reported the closing of an exclusive license agreement with GSK for BREXAFEMME® (Ibrexafungerp Tablets). SCYNEXIS received an upfront pay...
August 14, 2023
SCYNEXIS reported the closing of an exclusive license agreement with GSK for BREXAFEMME® (Ibrexafungerp Tablets). SCYNEXIS received an upfront payment of $90 million upon deal close.SCYNEXIS announced the